专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2008112772A2 GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM CHILDREN WITH DIABETES 审中-公开
标题翻译：来自患有糖尿病的儿童的外周血单核细胞中的基因表达
公开(公告)号：WO2008112772A2
公开(公告)日：2008-09-18
申请号：PCT/US2008056674
申请日：2008-03-12
申请人： BAYLOR RES INST , UNIV TEXAS , PASCUAL MARIA VIRGINIA , BANCHEREAU JACQUES F , CHAUSSABEL DAMIEN , KAIZER ELLEN , WHITE PERRIN C
发明人： PASCUAL MARIA VIRGINIA , BANCHEREAU JACQUES F , CHAUSSABEL DAMIEN , KAIZER ELLEN , WHITE PERRIN C
IPC分类号： A61K31/70 , A61K38/00 , A61P3/10 , C12Q1/02 , C12Q1/68 , C40B30/04 , G01N33/53
CPC分类号： C12Q1/6883 , A61K38/1793 , A61K45/06 , C12Q1/6837 , C12Q2600/158 , G01N2333/545 , G01N2333/90245 , G01N2800/042
摘要： The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-lß (ILlB), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL- lß antagonists sufficient to spare pancreatic beta cells, including an anti-IL-lß receptor and downstream activators.
摘要翻译：本发明包括通过测定表1中列出的一种或多种基因的表达水平来检测，评估，诊断，追踪和治疗1型糖尿病的组合物，方法和系统（例如白细胞介素-Iβ（IL1B）），早期生长反应基因3（EGR3）和前列腺素 - 内切酶合酶2（PTGS2））。本发明还包括用于治疗有需要的患者的组合物和方法，所述组合物具有治疗有效量的一种或多种足以使胰腺β细胞（包括抗IL-1β受体和下游激活剂）不足的IL-1β拮抗剂的组合物。

22. 发明申请

WO2008097870A2 AGENTS THAT ENGAGE ANTIGEN - PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC- ASGPR) 审中-公开
标题翻译：携带抗原的细胞 - 通过细胞核心蛋白质受体（DC-ASGPR）提供细胞
公开(公告)号：WO2008097870A2
公开(公告)日：2008-08-14
申请号：PCT/US2008052865
申请日：2008-02-02
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
发明人： BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
IPC分类号： C12N5/06 , A61K35/12 , A61K39/00 , A61K39/395 , A61P37/00 , C07K16/18 , C12N9/00
CPC分类号： A61K39/145 , A61K47/6849 , A61K51/1027 , A61K2039/5154 , C07K14/005 , C07K14/195 , C07K14/37 , C07K14/405 , C07K14/435 , C07K16/28 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/74 , C07K2317/75 , C07K2317/92 , C12N5/0639 , C12N7/00 , C12N2760/16122 , C12N2760/16134
摘要： The present invention includes compositions and methods for making and using anti DC- ASGPR antibodies that can, e.g., activate DCs and other cells.
摘要翻译：本发明包括用于制备和使用可以例如激活DC和其他细胞的抗DC-ASGPR抗体的组合物和方法。

23. 发明申请

WO2004050855A3 RAPID ONE-STEP METHOD FOR GENERATION OF ANTIGEN LOADED DENDRITIC CELL VACCINE FROM PRECURSORS 审中-公开
标题翻译：用于从前体产生抗原负载的细胞真菌的快速一步法
公开(公告)号：WO2004050855A3
公开(公告)日：2005-02-03
申请号：PCT/US0338553
申请日：2003-12-04
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , PALUCKA ANNA K
发明人： BANCHEREAU JACQUES F , PALUCKA ANNA K
IPC分类号： A61K39/00 , C12N5/02 , C12N5/0784 , A01N63/00 , A61K45/00 , A61K47/00 , C12N5/00 , C12N5/06
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/5154 , C12N5/0639 , C12N2501/22 , C12N2501/25
摘要： A one-step method for producing antigen loaded antigen-presenting cells from monocytes ex vivo has been found which comprises contacting the monocytes with a composition comprising an activator such as TNF alpha preferably in combination with at least one growth factor such as GM-CSF and at least one soluble or particulate antigen. According to the methods of the present invention, antigen-loaded dendritic cell vaccines can be generated within as little as three (3) days. In another method of the present invention, antigen loaded antigen-presenting cells are produced from monocytes ex vivo by contacting the monocytes with TNF alpha and granulocyte-macrophage colony stimulating factor at one time point to form antigen-presenting cells and then contacting antigenpresenting cells with soluble or particulate antigenic material at a second time point to form antigen loaded antigen-presenting cells, wherein the antigen loaded antigen-presenting cells are produced in less than four days. The present invention also includes a vaccine which comprises monocyte-derived antigen loaded antigen-presenting cells, wherein the antigenpresenting cells are composed of two or more subsets selected from the group consisting of Langerhans cells with surface markers (CD 1 a+ CD207+); interstitial dendritic cells with surface markers (CD 1a+ CD207-); double negative dendritic cells with surface markers 20 (CD 1 a-CD 14-); and dendritic cells with surface markers (CD 14+ CD 1 a- CD209+).
摘要翻译：已经发现从体外从单核细胞产生抗原负载抗原呈递细胞的一步法包括使单核细胞与包含活化剂如TNFα的组合物接触，优选与至少一种生长因子如GM-CSF和至少一种可溶或微粒抗原。根据本发明的方法，可以在短短三（3）天内产生抗原负载的树突状细胞疫苗。在本发明的另一种方法中，抗原呈递细胞由单核细胞通过单核细胞与TNFα和粒细胞 - 巨噬细胞集落刺激因子在一个时间点接触形成抗原呈递细胞，然后将抗原呈递细胞与可溶性或微粒状抗原物质，以形成抗原负载的抗原呈递细胞，其中抗原呈递细胞在不到四天内产生。本发明还包括一种疫苗，其包含单核细胞衍生的抗原负载抗原呈递细胞，其中所述抗原呈递细胞由两个或更多个选自具有表面标记的朗格汉斯细胞（CD1a + CD207 +）的子集组成; 具有表面标志物的间质树突状细胞（CD 1a + CD207-）; 具有表面标记20的双负性树突状细胞（CD 1 a-CD 14-）; 和具有表面标志物的树突状细胞（CD14 + CD11a-CD209 +）。

24. 发明申请

WO2011032161A3 VACCINES DIRECTED TO LANGERHANS CELLS 审中-公开
标题翻译：疫苗被导入朗格汉斯细胞
公开(公告)号：WO2011032161A3
公开(公告)日：2011-08-25
申请号：PCT/US2010048800
申请日：2010-09-14
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , ZURAWSKI SANDRA , ZURAWSKI GERARD , KLECHEVSKY EYNAV , OH SANGKON
发明人： BANCHEREAU JACQUES F , ZURAWSKI SANDRA , ZURAWSKI GERARD , KLECHEVSKY EYNAV , OH SANGKON
IPC分类号： A61K39/395 , A61K38/16 , A61K38/17 , A61P25/00 , A61P35/00
CPC分类号： C07K16/2896 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/505 , A61K2039/5154 , A61K2039/55561 , A61K2039/6056 , C07K14/005 , C07K14/4748 , C07K16/2851 , C07K2319/00 , C07K2319/33 , C12N7/00 , C12N2740/16034 , C12N2760/16134
摘要： The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy- terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.
摘要翻译：本发明包括分离的抗Langerin疫苗，在分离的抗Langerin抗体的羧基末端制备和使用分离的抗Langerin抗体或其结合片段和一个或多个抗原肽的方法，其中当两个或更多个抗原肽存在时，肽被包含至少一个糖基化位点的一个或多个接头肽分开。本发明还包括用于表达抗Langerin抗原递送载体的分离载体及其制备和用途。

25. 发明申请

WO2011066008A3 BLOOD TRANSCRIPTIONAL SIGNATURE OF ACTIVE VERSUS LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION 审中-公开
标题翻译：活动性血清MYCOBACTERIUM TUBCCOSOS感染的血液转录水平
公开(公告)号：WO2011066008A3
公开(公告)日：2011-07-21
申请号：PCT/US2010046042
申请日：2010-08-19
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , CHAUSSABEL DAMIEN , O'GARRA ANNE , BERRY MATTHEW , KON ONN MIN , MEDICAL RES COUNCIL ON BEHALF OF THE NAT INST FOR MEDICAL RES , IMP COLLEGE HEALTHCARE NHS TRUST
发明人： BANCHEREAU JACQUES F , CHAUSSABEL DAMIEN , O'GARRA ANNE , BERRY MATTHEW , KON ONN MIN
IPC分类号： C12Q1/68 , C12N15/31 , C12R1/32 , G01N33/15
CPC分类号： C12Q1/689 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
摘要： The present invention includes methods, systems and kits for distinguishing between active and latent Mycobacterium tuberculosis infection in a patient suspected of being infected with Mycobacterium tuberculosis, the method including the steps of obtaining a patient gene expression dataset from a patient suspected of being infected with Mycobacterium tuberculosis; sorting the patient gene expression dataset into one or more gene modules associated with Mycobacterium tuberculosis infection; and comparing the patient gene expression dataset for each of the one or more gene modules to a gene expression dataset from a non-patient; wherein an increase or decrease in the totality of gene expression in the patient gene expression dataset for the one or more gene modules is indicative of active Mycobacterium tuberculosis infection.
摘要翻译：本发明包括用于区分疑似感染结核分枝杆菌的患者中的活性和潜在结核分枝杆菌感染的方法，系统和试剂盒，所述方法包括以下步骤：从疑似感染分枝杆菌的患者获得患者基因表达数据集结核; 将患者基因表达数据集分类成与结核分枝杆菌感染相关的一个或多个基因模块; 以及将所述一个或多个基因模块中的每一个的患者基因表达数据集与来自非患者的基因表达数据集进行比较; 其中所述一个或多个基因模块的患者基因表达数据集中基因表达的总和的增加或减少指示活动性结核分枝杆菌感染。

26. 发明申请

WO2010104748A3 ANTIGEN PRESENTING CELL TARGETED ANTI-VIRAL VACCINES 审中-公开
标题翻译：抗原呈递细胞靶向的反病毒疫苗
公开(公告)号：WO2010104748A3
公开(公告)日：2011-03-03
申请号：PCT/US2010026273
申请日：2010-03-04
申请人： BAYLOR RES INST , ZURAWSKI GERARD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , LEVY YVES , MONTES MONICA
发明人： ZURAWSKI GERARD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , LEVY YVES , MONTES MONICA
IPC分类号： C07K19/00 , A61K39/12 , A61K39/395 , C07K16/08 , C12N15/62 , C12N15/63
CPC分类号： A61K39/0011 , A61K2039/6056 , C07K14/435 , C07K16/2878 , C07K2319/00 , C07K2319/33 , C07K2319/91
摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
摘要翻译：本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。

27. 发明申请

WO2010009346A8 HIV VACCINE BASED ON TARGETING MAXIMIZED GAG AND NEF TO DENDRITIC CELLS 审中-公开
标题翻译：基于针对树突细胞的最大化GAG和NEF的HIV疫苗
公开(公告)号：WO2010009346A8
公开(公告)日：2010-08-19
申请号：PCT/US2009050903
申请日：2009-07-16
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , ZURAWSKI GERARD , FLAMAR ANNE-LAURE , COBB AMANDA , MEAD HOLLY , MONTES MONICA
发明人： BANCHEREAU JACQUES F , ZURAWSKI GERARD , FLAMAR ANNE-LAURE , COBB AMANDA , MEAD HOLLY , MONTES MONICA
IPC分类号： A61K39/12 , A61K39/395
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K47/646 , A61K47/6843 , A61K47/6849 , C07K16/2878 , C07K2319/01 , C07K2319/035 , C07K2319/30 , C07K2319/33 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cy clin D1.
摘要翻译：本发明包括用于制备和使用疫苗的组合物和方法，所述疫苗包括与工程化Gag抗原连接的DC特异性抗体或其片段以形成抗体 - 抗原复合物，其中所述Gag抗原不易被蛋白水解降解去除与工程化的Nef抗原连接的一个或多个蛋白水解位点或DC特异性抗体或其片段以形成抗体 - 抗原复合物，其中所述Nef抗原包含增加抗体 - 抗原复合物分泌的一种或多种密码子选择优化，或两者，其中疫苗能够引发针对Gag p17，Gag p24，Nef和/或Cy clin D1的HIV特异性T细胞免疫应答。

28. 发明申请

WO2009149397A3 RESPIRATORY SYNCYTIAL VIRUS RENDERS DENDRITIC CELLS TOLEROGENIC 审中-公开
标题翻译：呼吸道同类病毒Renders DENDRITIC CELLS TOLEROGENIC
公开(公告)号：WO2009149397A3
公开(公告)日：2010-03-25
申请号：PCT/US2009046482
申请日：2009-06-05
申请人： BAYLOR RES INST , CONNOLLY JOHN E , BANCHEREAU JACQUES F , GILL MICHELLE A
发明人： CONNOLLY JOHN E , BANCHEREAU JACQUES F , GILL MICHELLE A
IPC分类号： A61K39/12 , A61P3/10 , A61P19/02 , A61P31/12
CPC分类号： A61K39/001 , A61K2035/122 , A61K2039/5154 , C12N5/064 , C12N2760/16111 , C12N2760/18511
摘要： The present invention includes compositions, methods and systems for inducing immune tolerance using antigen presenting cells by infecting isolated antigen presenting cells with an effective amount of respiratory syncytial virus (RSV) or portions thereof sufficient to infect the antigen presenting cells and contacting CD4+, CD8+ or both CD4+ T cells and CD8+ T cells with the RSV-infected antigen presenting cells, wherein the CD4+, CD8+ or both CD4 and CD8+ T cells are rendered tolerogenic as measured in vitro by a mixed leukocyte reaction.
摘要翻译：本发明包括用抗原呈递细胞诱导免疫耐受的组合物，方法和系统，其通过用有效量的呼吸道合胞病毒（RSV）或其部分感染分离的抗原呈递细胞，其足以感染抗原呈递细胞并接触CD4 +，CD8 +或具有RSV感染的抗原呈递细胞的CD4 + T细胞和CD8 + T细胞都是CD4 +，CD8 +或CD4 + CD8 + T细胞都具有耐受性，通过混合白细胞反应体外测定。

29. 发明申请

WO2008103953A3 ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 (LOX-1) 审中-公开
标题翻译：通过致敏细胞LECTIN-like氧化LDL受体-1（LOX-1）激活人抗原呈递细胞
公开(公告)号：WO2008103953A3
公开(公告)日：2008-10-16
申请号：PCT/US2008054792
申请日：2008-02-22
申请人： BAYLOR RES INST , BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
发明人： BANCHEREAU JACQUES F , OH SANGKON , ZURAWSKI GERARD , ZURAWSKI SANDRA , LI DAPENG
IPC分类号： C07K16/00 , A61K39/00
CPC分类号： A61K47/48369 , A61K2039/5154 , A61K2039/55516 , C07K16/28 , C07K2317/92 , C07K2319/01 , C07K2319/33
摘要： The present invention includes compositions and methods for targeting the LOX-I receptor on immune cells and uses for the anti-LOX-1 antibodies.
摘要翻译：本发明包括用于靶向免疫细胞上的LOX-1受体的组合物和方法以及抗LOX-1抗体的用途。

30. 发明申请

WO2010104749A3 ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES 审中-公开
标题翻译：抗原呈递细胞靶向癌症疫苗
公开(公告)号：WO2010104749A3
公开(公告)日：2011-02-24
申请号：PCT/US2010026275
申请日：2010-03-04
申请人： BAYLOR RES INST , ZURAWSKI GERALD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , LEVY YVES , MONTES MONICA , KLUCAR PETER , AKAGAWA KEIKO
发明人： ZURAWSKI GERALD , BANCHEREAU JACQUES F , FLAMAR ANNE-LAURE , LEVY YVES , MONTES MONICA , KLUCAR PETER , AKAGAWA KEIKO
IPC分类号： C07K19/00 , A61K39/395 , A61P35/00 , C07K16/30 , C12N15/62 , C12N15/63
CPC分类号： A61K39/0011 , A61K2039/6056 , C07K14/435 , C07K16/2878 , C07K2319/00 , C07K2319/33 , C07K2319/91
摘要： The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
摘要翻译：本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的新组合物以将抗原递送至抗原呈递细胞的组合物和方法。在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗CD40抗体或其片段连接的一种或多种抗原肽，包括人源化抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式